Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Feb 27, 2025 · 10-K · 58 days after period end · 0001636282-25-000020
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $168.00K | $3.64M |
| Net Income | -$56.30M | -$63.18M | -$18.82M | -$20.45M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end
